|Articles|October 28, 2015

Valeant Responds to Drug Distribution Criticisms

October 28, 2015.

According to a recent report from Citron Research originally highlighted in the New York Times (Oct. 19, 2015), Valeant is using phantom drug distribution companies to manipulate distribution numbers to auditors. Philidor Rx Services came on the media’s radar when Valeant CEO J. Michael Pearson said during a quarterly earnings call that Valeant had purchased an option to acquire Philidor in 2014.

BioPharm International's Randi Hernandez reports on Valeant's response here.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Valeant Responds to Drug Distribution Criticisms

Related Content

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Additive Manufacturing's Application in Pharma and Biotech

Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor

The ROI of Smarter Trials: Q&A with Raj Indupuri

Trending on PharmExec

The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market

Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion

Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last

Catalent Announces Expanded Partnership with Nanoscope Therapeutics

Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization